Page 1,229«..1020..1,2281,2291,2301,231..1,2401,250..»

Global Epigenetics Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and Application…

Posted: December 15, 2019 at 2:49 am

Christmas Is A Season Not Only Of Rejoicing But Of Reflection. Avail Up To 40% Off On All Our Qualitative Research Reports. Be the Santa of Your Happy Business!

Worldwide Epigenetics Market is a report created by Global Marketers.Biz. The Epigenetics market research report is segmented on the basis of device, technology, application, and region. Primary and secondary research efforts were invested to arrive at intelligent conclusions presented in the report on the global target market. Findings and conclusions of the research were verified by experts from the industry before including it in the report.

It is a compilation of analytical study based on historical records, current, and upcoming statistics and future developments of the Epigenetics Industry. Based on the study, Global Marketers.Biz predicts that the market will see a comparable and steady CAGR growth.

Epigenetics Market Segmentation By Type, Applications & Regions

Fill Out Details To Receive FREE Sample Report Copy Here: https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #request_sample

The report covers a forecast and an analysis of the Epigenetics Market on a global and regional level. The ancient data is given from 2013-2018 and the estimate period is from 2019-2023 based on revenue (USD Billion). The Epigenetics market was estimated at XX Million US$ in 2019 and is probable to grasp XX Million US$ by 2023, at a CAGR of XX% throughout 2019-2023.

The study is also compiled on the basis of the latest and upcoming innovations, opportunities and trends. In addition to SWOT analysis, the report also contains a detailed market analysis outlining every major player in the process.

Avail Up To 40% Off On All Our Qualitative Research Reports.

Inquire Before Buying Or Ask For More Details: https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #inquiry_before_buying

The Report Answers the key Questions related to the Epigenetics Market:

What are the important trends and dynamics?

Where will most development take place in the long term?

What does the competitive landscape look like?

What the openings are yet to come?

TOC of Epigenetics Market Report Includes:

1. Industry Overview of Epigenetics

2. Industry Chain Analysis of Epigenetics

3. Manufacturing Technology of Epigenetics

4.Major Manufacturers Analysis of Epigenetics

5. Global Productions, Revenue and Price Analysis of Epigenetics by Regions, Creators, Types and Applications

6. Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Epigenetics 2013-2019.

7. Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Epigenetics by Regions

8. Gross and Gross Margin Examination of Epigenetics

9. Marketing Traders or Distributor Examination of Epigenetics

10. Worldwide Impacts on Epigenetics Industry,

11. Development Trend Analysis of Epigenetics

12. Contact information of Epigenetics

13. New Project Investment Feasibility Analysis of Epigenetics

14. Conclusion of the Global Epigenetics Industry 2019 Market Research Report

Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Customization Service of the Report:

Global Marketers.biz provides customization of reports as per your need. The report can be altered to meet your requirements. Contact our sales team, who will guarantee you to get a report that suits your needs.

Please get in touch with our sales squad (Alex@globalmarketers.biz).

For more relevant information visit https://www.globalmarketers.biz/

Avail Up To 40% Off On All Our Qualitative Research Reports.

Request for more detailed information (TOC and Sample): https://www.globalmarketers.biz/report/life-sciences/global-epigenetics-industry-market-research-report/2687 #table_of_contents

Here is the original post:
Global Epigenetics Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and Application...

Posted in Epigenetics | Comments Off on Global Epigenetics Market | 2018-2023 Growth Analysis, Business Opportunities, Sales, Revenue, Gross Margin, Advance Technology and Application…

Epigenetics Market Size Analysis, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2019 To 2025 – The Market Stats News

Posted: December 15, 2019 at 2:49 am

Epigenetics Market research now available at Brand Essence Research encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Epigenetics industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Epigenetics market in the forecast timeline.

The Epigenetics Market Report provides key strategies followed by leading Epigenetics industry manufactures and Sections of Market like- product specifications, volume, production value, Feasibility Analysis, Classification based on types and end user application areas with geographic growth and upcoming advancement. The Epigenetics market report provides comprehensive outline of Invention, Industry Requirement, technology and production analysis considering major factors such as Revenue, investments and business growth.

Request for Sample of this Report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Sample

The well-established players in the market are:

This report for Epigenetics Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Drivers & Hindrances of the Epigenetics market: How does the report explicate on the same

The report unveils the driving parameters affecting the commercialization chart of this industry.

The Epigenetics market research report further illustrates the various challenges that this market is prone to as well as its impact on the market trends.

An important aspect that the report sets focus on is the market concentration ratio for the predicted timeframe.

The geographical spectrum of the business and its consequence on the Epigenetics market:

The report segments the Epigenetics market into USA, Europe, Japan, China, India, South East Asia depending on the regional scope of this business

Extensive data about the product consumption across innumerable sections as well as the valuation developed by these regions is also explained in the report.

The study puts emphasis on data concerning the consumption market share across these regions, as well as the market share attained by every region and product consumption growth rate.

Market segment by Type, the product can be split into

Market segment by Application, split into

Market segment by Regions/Countries, this report covers

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

Request Customization of this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Methodology

Key highlights and essential features of the report:

1) Which major players are presently listed in the report?Here are the companies that are presently listed in the report: Abcam Plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Epizyme Inc., Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation others.

**List of the firms stated above might differ in the final report dependent on a merger, name change, and other factors.

2) Can you list or add new firms as per our requirement?Yes,we can list or add new firm as per the requirement by client in the report. The final confirmation regarding the same must be provided by the research team subject to difficulty of survey.

**Availability of data will be confirmed after research in case of a privately held firm. Maximum 3 companies can be included at no additional charge.

3) Which all regional categorization are covered? Is it possible to add any specific country?Presently, our research report offers special focus and attention on the following areas:Europe, United States, Japan, China, India, Southeast Asia, and Central & South America

**Maximum one country of specific interest can be added at no extra charge. Charges will be applied for the addition of extra countries or regions.

4) Can the addition of extra Market breakdown or segmentation is possible?Yes, the addition of extra Market breakdown or segmentation is possibly dependent on the difficulty of survey and availability of data. On the other hand, detailed sharing of the requirements with our research team is a must before providing final confirmation to the client.

More Details on this Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=68491&RequestType=Customization

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Epigenetics Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Epigenetics Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Epigenetics Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Epigenetics Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Epigenetics Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Epigenetics Market.

Market Forecast:Here, the report offers a complete forecast of the global Epigenetics Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix:Here, we have provided a disclaimer, our data sources, data triangulation, research programs, market breakdown and design, and our research approach.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

sales@brandessenceresearch.com

View post:
Epigenetics Market Size Analysis, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2019 To 2025 - The Market Stats News

Posted in Epigenetics | Comments Off on Epigenetics Market Size Analysis, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2019 To 2025 – The Market Stats News

Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) – The Broch Herald

Posted: December 15, 2019 at 2:48 am

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both businesses.

Risk & Volatility

Brainstorm Cell Therapeutics Inc. has a 1.37 beta, while its volatility is 37.00% which is more volatile than Standard and Poors 500. Cara Therapeutics Inc. has a 2.4 beta and it is 140.00% more volatile than Standard and Poors 500.

Liquidity

Brainstorm Cell Therapeutics Inc.s Current Ratio and Quick Ratio are 0.4 and 0.4 respectively. The Current Ratio and Quick Ratio of its competitor Cara Therapeutics Inc. are 4.2 and 4.2 respectively. Cara Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

Brainstorm Cell Therapeutics Inc. and Cara Therapeutics Inc. Ratings and Recommendations are available in the next table.

Brainstorm Cell Therapeutics Inc.s upside potential currently stands at 133.77% and an $9 average target price. Meanwhile, Cara Therapeutics Inc.s average target price is $35.67, while its potential upside is 115.27%. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than Cara Therapeutics Inc. as far as analyst opinion.

Institutional and Insider Ownership

Brainstorm Cell Therapeutics Inc. and Cara Therapeutics Inc. has shares owned by institutional investors as follows: 9.5% and 66.7%. Insiders owned roughly 10.4% of Brainstorm Cell Therapeutics Inc.s shares. Insiders Competitively, owned 2.2% of Cara Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. was less bullish than Cara Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companys lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More here:
Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) - The Broch Herald

Posted in Connecticut Stem Cells | Comments Off on Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) – The Broch Herald

How our screen stories of the future went from flying cars to a darker version of now – The Conversation AU

Posted: December 15, 2019 at 2:45 am

Fans of Ridley Scotts 1982 masterpiece Blade Runner returned to cinemas last month for an unusual milestone: history catching up with science fiction.

Blade Runner opens in Los Angeles, in November 2019. Furnaces burst flames into the perennial night and endless rain. Flying cars zoom by. The antihero film-noir detective, Deckard (Harrison Ford) has seen too much, drinks too much, and misses his mother between retiring replicants.

As in Back to the Future day, (October 21, 2015), which marked Marty McFlys journey into the future in the 1989 film, the Blade Runner screenings came with a flurry of discussion about what the filmmakers got right and wrong. Environmental collapse, yes. But where are our flying cars?

So: what now that the future is here?

Our current versions of near future stories - namely the television series Black Mirror (now on Netflix) and SBSs Years and Years - explore more extreme versions of the present.

Charlie Brookers Black Mirror is an anthology of standalone episodes, produced between 2011 and 2019, each set in a slightly different, undated, near future.

Years and Years, written by Russell T. Davies, bravely spans 2019 to 2034 with each episode leaping forward a few years through striking montages of fictional news events: the collapse of the European Union, the US leaving the United Nations, catastrophic flooding, mass migration, widespread homelessness.

We are in a very familiar world. The near is depicted in a realistic way through identifiable locations, documentary-style visuals, news footage, and lifelike dialogue.

Back in the real world, the future in the 21st century is unfolding in the palm of our hands. Elections are won and lost on social media, Sydney is covered in smoke. The rate at which technology is altering our lives is rivalled only by the rate were transforming our planet.

These shows explore these rates of change. In a 2016 episode of Black Mirror, Nosedive, every interpersonal interaction becomes a transaction: an extreme version of Uber Ratings with Chinas Social Credit System.

Read more: Chinas Social Credit System puts its people under pressure to be model citizens

Lacie (Bryce Dallas Howard) is an ambitious young professional excited by the opportunities higher ratings open up, such as discounts on luxury apartments, but being pleasant to her barista and workmates only gets her so far. So begins a perilous spiral of trying too hard to be liked, echoing the personality-as-product phenomenon of social media influencers around the world.

The standalone episode format of Black Mirror means it can be challenging to develop empathy for characters, consequently the interest often rests on the single concept or final twist. The episode Striking Vipers explores the possibility of extra-marital love between best mates in Virtual Reality; Hang the DJ envisions dating apps as an authoritarian apparatus.

Most episodes are neatly wrapped up for viewers to escape to for pure entertainment but also to escape from each dystopian possibility.

In Years and Years, we follow one Mancunian family over 19 years. The series opens with Trump re-elected for a second term. In the UK, the unconventional populist Four Star Party, led by straight-speaking Vivienne Rook (Emma Thompson), rides to success on the back of social instability.

Sci-fi concepts are introduced early on so we can explore their evolution and implications. In the first episode, teenager Bethany declares herself trans. As progressive parents, Stephen and Celeste immediately comfort their child, who they presume is transsexual.

Bethany shrugs, Im not transsexual Im transhuman. A concept not lost on Blade Runner fans who may be aware of transhumanist gatherings in Los Angeles in the 1980s, transhumanism is premised on the idea that humans have breached evolutionary constraints through science and technology. Biology is a restriction to the possibility of eternal life.

Read more: Super-intelligence and eternal life: transhumanism's faithful follow it blindly into a future for the elite

Disgust and dismay ensue from parents unable to comprehend why their child wants to rid her flesh and live forever as data. Through the course of the series we see how Bethanys transhuman ambitions influence her personal relationships, health, career trajectory, and political activism.

It even starts to feel normal.

Years and Years delicately resists portraying a dystopia, allowing room for technology to demonstrate a positive influence on society. Seor, the ubiquitous virtual assistant, connects the Lyons family whenever they wish. Like Alexa or Siri, Seor is always at hand to answer questions but more importantly, facilitates an intimacy that could easily be lost to technological isolation.

In 2029, grandmother Muriel digs up the dusty digital assistant Seor because she misses its company. By now, virtual assistants are embedded into the walls and omnipresent digital cloud but the Luddite grandmother resists.

I like having something to look at, Im not talking to the walls like Shirley Valentine, she says.

Its moments like these that remind us of our agency over technology and hint at its revolutionary potential to connect us all.

While classics like Blade Runner looked to the future to ignite our technological desires, near-future fiction reveals how new technologies are injected into our lives with little choice as to whether we should adopt them and little thought to their long-term appropriateness and sustainability.

These shows ask us to be critical of what might seem like minor developments in technology and politics. In an age of rapidly changing political landscapes and the climate catastrophe, it can feel like we are approaching the final frontier. In creating stories set in the near, instead of the far, future, science fiction provides valuable lessons for the present.

In other words: the choices we fail to stand up for in the near-future may prevent us from having a distant future at all.

Here is the original post:
How our screen stories of the future went from flying cars to a darker version of now - The Conversation AU

Posted in Transhumanism | Comments Off on How our screen stories of the future went from flying cars to a darker version of now – The Conversation AU

Living in the real AI world – Covalence

Posted: December 15, 2019 at 2:45 am

Photo by Frank V. via Unsplash

Alexa seems to know what I want to watch and when, Google search seems to know my wishes too when I search for my favorite restaurant online and perhaps even more interesting is that even the success of my 401(k) investments will ultimately be influenced by artificial intelligence (AI) that seemingly is becoming more real by the day.

There are a growing number of hedge fund managers even who rely on AI to outperform the market and to complete trades faster than our human mind can contemplate. They tend to exponentially outperform their non-AI counterparts with super-human ability.

So when one reads about the idea of an AI God that gained steam a couple of years ago, when self-driving car engineer Anthony Levandowski opened The Way of the Future Church, it seems as though the future has easily slipped into our present day-to-day activities in the blink of an eye.

According to The Way of the Future Churchs website, it is a movement about creating a peaceful and respectful transition of who is in charge of the planet from people to people plus machines. It is about something called the singularity point a point in time that is fast approaching when machine intelligence will surpass that of its human makers. Remember The Matrix trilogy, anyone?

The classic line by the films hero, Neo, comes to mind: Ever have that feeling where youre not sure if youre awake or dreaming? Thats a whole other Silicon Valley philosophy that we are merely in a simulation. But thats another topic, entirely.

The idea of people and machines being in charge, however, seems far from comforting and far removed from a Lutheran ideal of grace in removing God from the equation altogether.

This month Lutheran theologian Ted Peters dives into many of the thorny issues related to artificial intelligence and how some in the transhumanism community view it as a way of advancing our humanity beyond our physical bodies.

Countless movies and T.V. shows have taken on this topic including a popular Netflix series called Altered Carbon, where society simply views physical bodies as sleeves for ones uploaded consciousness that can be slotted over and over again into new bodies. Of course, there are problems and ethical dilemmas that give way to a dramatic story line.

Still, technology always seems to have a way making us feel smarter (thanks Google!) and almost invincible. That in its own right can be problematic, which is some of what Peters writes about this month.

Whether it is a new medical device, an app on your smart phone or even your Wifi connectivity, it is well worth remembering all have a piece of Gods very creation within it as do the technology developers who creatively make the invisible, visible every day.

Considering technology as our ultimate savior and life-giver sans God is what is at issue. Worshipping a powerful algorithmic God is short sighted too as we realize that even within the code itself there is the hand of a human being created in the image of a loving God who in turn supports the human intellect that ultimately wants to surpass itself.

Editor

Susan is an author with a long-time interest in religion and science. She currently edits Covalence, the Lutheran Alliance for Faith, Science and Technologys online magazine. She has written articles in The Lutheran and the Zygon Center for Religion and Science newsletter. Susan is a board member for the Center for Advanced Study of Religion and Science, the supporting organization for the Zygon Center and the Zygon Journal. She also co-wrote Our Bodies Are Selves with Dr. Philip Hefner and Dr. Ann Pederson.

Related posts

The rest is here:
Living in the real AI world - Covalence

Posted in Transhumanism | Comments Off on Living in the real AI world – Covalence

‘The Expanse’ Season 4’s biggest highlight is eventual coming together of Belters and New Terra – MEAWW

Posted: December 15, 2019 at 2:45 am

This article contains spoilers for Season 4

The latest and fourth season of 'The Expanse' is all about the quest for transhumanism while Holden and Co. struggle to weather foreign planets and proto-molecules trying to sabotage everything they are fighting for. Amidst all of that crazy science and action taking place, it is the coming together of the two primary groups of rivals the Belters and the New Terra trying to take over Ilus and establish their authority on the planet, to fight the big bad that steals the show.

The focal problem that most of the action revolves around in Season 4 of 'The Expanse' is the evergoing struggle of human biology trying to survive in an environment best suited for the extraterrestrial. While humans aren't used to breathing the same air as other planetary species, it automatically becomes difficult for them to build a life on Ilus. Things definitely don't help the populace on Ilus the Belters, when the RCE or New Terra barge in on their territory, trying to do what would be called on Earth a brazen urbanizing or gentrifying of their community.

With the atmosphere making it difficult for both the sections of human populace on Ilus to breathe, even with the partial oxygen that allows them to function properly, the fight for survival soon turns into a fight amongst themselves. The New Terra wants to establish their authority on Ilus and the materials it possesses, and the Belters aren't ready to give their land up. They feel threatened under the elaborate machines and mechanism of the New Terra, who even though probably mean well under Chrisjen's leadership, but come off as a fascist government trying to take over another community's life and livelihood.

While certain crucial plot points from the novel are definitely borrowed to escalate the story, the execution is somewhat swift without really delving deep into why the twists happened, or what the repercussions could amount to. It is only when Ilus, which is practically a colossal barren rock with alien particles sticking out, starts turning on the humans trying to make a home out of it, that these humans unite to fight back. Particularly, a giant explosion on Ilus is what brings the two forces of human societies together and that's right where things pace up to give us 'The Expanse' we have loved and adored so avidly since it hit the SyFy network back in 2015.

Sadly, we couldn't get much of a foray into what happens after the two join forces or how they overcome the explosive situation on Ilus due to the permissible episodes that were granted for early screening and press purposes ending right at this point. But it's safe to conclude that after five long episodes of just basically two rival parties fighting and holding each other off, this beautiful coming together is what has proved to be the highlight of the show so far.

'The Expanse' Season 4 premieres on Friday, December 13, only on Amazon Prime.

Go here to see the original:
'The Expanse' Season 4's biggest highlight is eventual coming together of Belters and New Terra - MEAWW

Posted in Transhumanism | Comments Off on ‘The Expanse’ Season 4’s biggest highlight is eventual coming together of Belters and New Terra – MEAWW

Five recent drug target discoveries for pancreatic cancer – Drug Target Review

Posted: December 13, 2019 at 6:58 pm

This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.

Scientists investigating pancreatic cancer have identified new targets which, with further research, could be the basis for developing future therapies. Listed below are five of the most recent target discoveries, in order of their journal publication dates, with the newest first.

Scientists at the Queen Mary University of London, UK and Zhengzhou University, China have developed a personalised vaccine system that may be able to delay the onset of pancreatic cancer.

Cells taken from mice, mutated chemically into pancreatic cancer cells and then infected with Adenovirus (AdV) as a prime or Vaccinia virus (VV) as a boost, create a vaccine product. The virus kills the cancerous cells in such a way that their antigens are released and are therefore able to prime the immune system to prevent pancreatic cancer returning.

Injection of the virus-infected cells into mice destined to develop pancreatic cancer doubled their survival rate, compared to their unvaccinated counterparts. The vaccine also delayed the onset of the condition in these mice.

Using cells from the recipient of the vaccine enables the immune system to respond to the exact antigens seen in tumour cells of the individual, resulting in a vaccine regime tailored to them.

Through this international collaboration, we have made progress towards the development of a prophylactic cancer vaccine against pancreatic cancer, said Professor Yaohe Wang, leader of the study, from Queen Mary University of London and the Sino-British Research Centre at Zhengzhou University in China.

Researchers at Sanford Burnham Prebys Medical Discovery Institute in the US have identified that a combination of two anti-cancer compounds, already approved for use to treat other cancers, shrank pancreatic tumours in mice.

Our study identifies a potential treatment combination that can immediately be tested against these aggressive tumours. We are already meeting with oncologists at Oregon Health & Science University, US to discuss how to advance this discovery into clinical evaluation, explained Dr Zeev Ronai, a professor in Sanford Burnham Prebys Tumor Initiation and Maintenance Program, also senior author of the study.

Scientists used L-asparaginase to starve pancreatic tumours of asparagine, an amino acid required by cells for protein synthesis. However, the tumour cells did not die, instead switching on a stress response pathway whereby they could produce asparagine themselves. Scientists then used an MEK inhibitor to block the stress response pathway, causing the pancreatic tumour to shrink.

L-asparaginase is already US Food and Drug Administration (FDA) approved to treat leukaemias and similarly the MEK inhibitor is approved for the treatment of solid tumours, including melanoma skin cancer.

This research lays the basis for the inhibition of pancreatic tumour growth by a combined synergistic attack based on asparagine restriction and MAPK signalling inhibition, says Dr Eytan Ruppin, chief of the Cancer Data Science Library at the National Cancer Institute (NCI) and co-author of the study.

Scientists from the Max Planck Institute for Biology of Ageing, Germany have identified that YME1L, a protease in the membrane of mitochondria, is activated when a cell uses glycolysis to produce energy anaerobically.

scientists were able to reduce tumour growth by switching off the glycolysis signalling pathway in the mitochondria

Cells adapt to oxygen deficiency by switching their energy supply to glycolysis, which ferments sugar without oxygen. This switch is often necessary in old age, as the cells in the body become poorly supplied with oxygen and nutrients.

Cancer cells can also face this problem; prior to angiogenesis, tumours are poorly perfused and so the tissue is deprived of oxygen. Oxidative stress in tumours drives the switch-on of multiple pathways. This includes the glycolysis pathway that alters the behaviour of the mitochondria to provide tumour cells with energy despite being starved of oxygen.

Scientists found that the YME1L protease is activated during the conversion to glycolysis. YME1L appears altered and breaks down various proteins in the organelles, preventing the formation of new mitochondria and causing the remaining organelles to change their metabolism. This process eventually stops as YME1L begins to degrade itself at high activity.

Researchers examined cancer cells originating from patients with pancreatic tumours and were able to reduce tumour growth by switching off the glycolysis signalling pathway in the mitochondria, with reproducible results both in the petri dish and in pancreatic tumours in mice.

There is currently no treatment available for pancreatic cancer. I believe that this protease can be a very interesting therapeutic target because we have seen that the signalling pathway is also active in human patients with pancreatic cancer, explained Thomas Langer, the Max Planck Director, continuing: However, there are no known substances that have an effect on this protease.

Researchers at the Crick Institute have identified cancer stem cells as a driver of pancreatic cancer growth. These cells can metastasise and differentiate into different tumour types to continue the spread of cancer.

Cancer stem cells appear at all stages of cancer growth so being able to identify where they are present could be vital in both targeting cancer and developing new treatments, according to the researchers. Analysis of gene expression in the cancer stem cells identified a protein, CD9, is present on tumour surfaces during development and when it is more established. This protein could therefore be used as a marker to help locate these cells.

A further development of the study established that this protein is not just a marker of cancer stem cells, but also promotes their malignant behaviour. By altering the amount of CD9 in tumour cells in mice, researchers found that reduced levels of this protein caused smaller tumours to form and increasing levels of CD9 created more aggressive cells able to form large tumours quickly.

These cells are vital to pancreatic cancer and if even just a few of them survive chemotherapy, the cancer is able to bounce back. We need to find effective ways to remove these cells and so stop them from fuelling cancer growth. However, we need more experiments to validate the importance of CD9 in human pancreatic cancer, says Victoria Wang, lead author and member of the Adult Stem Cell Laboratory at the Crick Institute.

A look into cancer stem cell metabolism also revealed CD9 increases the rate tumour cells take up glutamine, an amino acid which helps provide energy for cancer growth.

Now we know this protein is both linked to cancer stem cells and helps cancer growth, this could guide the development of new treatments that are targeted at the protein and so cut off the supply of glutamine to cancer stem cells, effectively starving the cancer, says Axel Behrens, corresponding author and group leader in the Adult Stem Cell Laboratory at the Crick Institute.

Scientists at Tel Aviv University, Israel have found that PJ34, a small molecule, causes human pancreatic cancer cells to self-destruct. The researchers tested PJ34 on xenografts (transplants) of human pancreatic tumours in mice.

this mechanism also exists in other types of cancer and therefore the treatment could be valuable for use on those resistant to current therapies

The mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively. This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death. Thus, cell multiplication itself resulted in cell death in the treated cancer cells, explains Professor Malca Cohen-Armon, project lead at Tel Aviv Universitys Sackler Faculty of Medicine.

The treatment consisted of daily PJ34 injections for 14 days and four weeks later there was a relative drop of 90 percent in the number of cancer cells within the tumours of the mice. Cohen-Armon also noted there were no adverse side-effects observed in the mice.

This mechanism similarly exists in other types of cancer and therefore the treatment could be valuable for use on those resistant to current therapies. The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin.

Read more:
Five recent drug target discoveries for pancreatic cancer - Drug Target Review

Posted in Oregon Stem Cells | Comments Off on Five recent drug target discoveries for pancreatic cancer – Drug Target Review

Why Sangamo Therapeutics Stock Sank Today – The Motley Fool

Posted: December 13, 2019 at 6:57 pm

What happened

Shares of Sangamo Therapeutics (NASDAQ:SGMO) were sinking 11.7% lower as of 3:28 p.m. EST on Tuesday. This marked the second consecutive day of double-digit-percentage declines for the biotech stock after Sangamo announced preliminary results on Monday from a phase 1/2 clinical study evaluating experimental gene-editing therapy ST-400 in treating rare blood disease transfusion-dependent beta thalassemia (TDT).

Those preliminary results were for the first three patients in Sangamo's Thales clinical trial targeting beta thalassemia. The good news was that all three patients receiving ST-400 quickly experienced reconstitution of their hematopoietic stem cells after gene editing as well as demonstrating neutrophil engraftment -- the first day where the patients' neutrophil counts were at least 500 cells per microliter for three consecutive days.

Image source: Getty Images.

The not-so-good news related to the adverse effects experienced by the patients. One patient experienced a serious adverse event with hypersensitivity during the ST-400 infusion, although the issue resolved by the end of the infusion. Also, another patient's fetal hemoglobin levels increased by less than 1 gram per deciliter through week 26 of the study. The goal of ST-400 is to boost fetal hemoglobin levels enough to minimize the negative effects of beta thalassemia.

University of Minnesota Associate Professor Angela Smith, a principal investigator of the Thales study, noted that "the full effects of the treatment may take as long as 12 to 18 months or more to manifest." She added, "Longer-term follow-up, including from additional patients, will be necessary to understand the safety profile and potential clinical benefit of ST-400 in beta-thalassemia."

Adrian Woolfson, Sangamo's head of research and development, stated, "Our understanding of ST-400 will continue to evolve as we follow the progress of these and additional patients in the coming year, and those dosed in Sanofi's BIVV003 clinical trial, which is evaluating the same gene-editing approach in sickle cell disease."

This cautious language from both Smith and Woolfson underscores the tentative nature of the preliminary results.

Investors will have to wait a while to learn just how much promise ST-400 holds. Sangamo expects to announce additional study results late next year after enrollment in the Thales study is completed and after all six patients in the study have been observed for longer periods.

Sangamo's last week or so has demonstrated the volatility associated with biotech stocks, especially those with no approved drugs on the market. Sangamo jumped last week on positive results from another study (of hemophilia gene therapy SB-525) but gave up those gains and then some on the news for ST-400.

Read more from the original source:
Why Sangamo Therapeutics Stock Sank Today - The Motley Fool

Posted in Minnesota Stem Cells | Comments Off on Why Sangamo Therapeutics Stock Sank Today – The Motley Fool

His life in ‘overtime,’ Penn doctor races to find better treatments for rare Castleman disease – PhillyVoice.com

Posted: December 13, 2019 at 6:54 pm

David Fajgenbaum's life went into overtime the moment a priest read his last rites in November 2010.

At least that's how the Penn Medicine immunologist views his last nine years.

That belief has reshaped the way Fajgenbaum confronts idiopathic multicentric Castleman disease, a rare immune system disorder that has dealt him five life-threatening blows. It's also changed the way he goes about his life.

"When you're in overtime, every second counts. You don't know how much time you have," said Fajgenbaum, a former quarterback at Georgetown University. "It really helps you focus in on what's important and what's not important."

For a while, Fajgenbaum said he "just hoped and prayed" that someone, somewhere, would find a cure and better treatment options for Castleman disease, which kills about 35% of its victims within five years of diagnosis. Then, he realized he might be that person.

That life lesson is among several that Fajgenbaum, 34, recounts in his new memoir, "Chasing My Cure: A Doctor's Race To Turn Hope Into Action." Fajgenbuam wrote the book partly in hopes of boosting awareness of Castleman disease, which has not gained the notoriety of other rare diseases despite its deadly nature.

"We shouldn't either hopeortake action we should hopeandtake action," Fajgenbaum said. "I'm here on the phone because of that turning point."

Idiopathic multicentric Castleman disease the most severe form of the disorder activates the bodys immune system, releasing an abundance of inflammatory proteins that can shut down the liver, kidneys and bone marrow. Relatively little is known about it.

Fajgenbaum, an assistant professor in Penn Medicine's Translational Medicine and Human Genetics division, has spearheaded efforts to identify more effective treatment options for people with Castleman disease. After all, he recognizes his clock may stop ticking at any moment.

Chemotherapy can keep the disease at bay for a while, but it's not a permanent solution, Fajgenbaum said. Patients tend to relapse after treatment, creating a vicious cycle that he knows all too well.

Thus far, the U.S. Food and Drug Administration only has approved one treatment siltuximab for Castleman disease. But it only works in about one-third of patients and Fajgenbaum is not one of them.

Fagjenbaum's research and his personal experience eventually led him to sirolimus, an immunosuppressant typically prescribed for kidney transplant patients. Because the drug inhibits activated T-cells, he suspected it might put his disease in remission.

"I knew if I did not start myself on a drug, there was no way I was going to make it," Fajgenbaum said.

Under the supervision of his doctor, Fajgenbaum began taking sirolimus after his last life-threatening hospitalization six years ago. At the time, Fajgenbaum was simply hoping he'd live long enough to marry his girlfriend, Caitlin something he said he once took for granted.

"The pre-overtime mentality is that we have all the time in the world, that if it's meant to be, it's meant to be," Fajgenbaum said. "But the overtime reality is that none of us have all the time in the world. If it's meaningful and important, then that's exactly what you should do."

Since Fajgenbaum began taking sirolimus, his symptoms have not flared up.

Now, he and Caitlin have a daughter, Amelia. And Fajgenbaum is leading clinical trials examining sirolimus' effectiveness against Castleman disease. Like siltuximab, the drug appears it may help some but not all people battling Castleman disease.

That has Fajgenbaum wondering how many other existing drugs have been overlooked as potential treatments for other diseases. It's another lesson that he expands upon in his book.

"Sometimes, solutions can be hiding in plain site," Fajgenbaum said. "This drug I'm on is in my neighborhood CVS all these years and no one had thought to try it. How many other things are like that ... in science or medicine?"

Since writing the book, Fajgenbaum said he has heard from all kinds of people who have faced challenging health diagnoses, whether it's cancer or some other rare disease.

It's definitely moving the needle, Fajgenbaum said. In September, the month the book was published, more people Googled Castleman disease than ever before. And more people have donated funds to the Castleman Disease Collaborative Network, an organization he co-founded to expedite research efforts.

"It's really been, in many ways, therapeutic to be able to share my story, the ups and the downs," Fajgenbaum said. "Even writing it was therapeutic. To bring back some tough memories, to expose them and to face them."

Sometimes, Fajgenbaum said, it's best to face the tough times with a sense of humor. That's a lesson he gained from his late mother, who died of cancer when he was at Georgetown.

Fajgenbaum recalled flying to Raleigh, North Carolina to see his mother after she had a brain tumor removed. He tentatively walked into her room alongside his family, unsure what to expect. He found his mom sitting, her head shaved and partly covered by a gauze wrap.

She pointed to her head and joked that she looked like the Chiquita banana lady.

"It was exactly what we needed," Fajgenbaum said. "It wasn't what my mom needed. She was going through a really tough time. It wasn't going to make her feel better. But she knew that it was going to make us feel better. By making that joke, it kind of relieved everything. It was like, you're still my mom, you're still you."

A few years later, Fajgenbaum found himself walking around the hospital with his father on New Year's Eve. This time, Fajgenbaum was the patient. His stomach was filled with 30 pounds of fluid, the result of his ill-functioning kidneys and liver.

As they passed the family waiting area, they stopped to help a man who was laying on the floor, noticeably drunk. The man thanked Fajgenbaum's father, wishing him and his "pregnant wife" the best of luck.

"We just burst into laughter," Fajgenbaum said. "I turned to my dad and said, 'Man, you've got an ugly wife.'

"If I hadn't had my mom's example ... maybe I would have just burst into tears and gone back to my room. Rather, that's hilarious. This drunk guy thinks I'm a pregnant woman because of the size of my belly."

That moment, nearly nine years ago, came just several weeks into Fajgenbaum's "overtime" session. He's overcome a lot since and learned a great deal. But he knows there's more work to be done for him and for others.

Follow John & PhillyVoice on Twitter: @WriterJohnKopp | @thePhillyVoiceLike us on Facebook: PhillyVoiceAdd John's RSS feed to your feed readerHave a news tip? Let us know.

Read the original:
His life in 'overtime,' Penn doctor races to find better treatments for rare Castleman disease - PhillyVoice.com

Posted in Human Genetics | Comments Off on His life in ‘overtime,’ Penn doctor races to find better treatments for rare Castleman disease – PhillyVoice.com

Gene repeats tied to autism may prevent anemia – Spectrum

Posted: December 13, 2019 at 6:54 pm

Pumping iron: A gene called BOLA2 helps proteins capture iron, which is crucial for red blood cells to transport oxygen.

Design Cells / Science Photo Library

IN BRIEF

Extra copies of a gene called BOLA2 predispose people to autism and may protect against iron deficiency, according to a new study1.

Repeats of the gene make people susceptible to deletion or duplication of a region on chromosome 16 that is tied to autism. The benefit of anemia prevention may explain why the repeats evolved despite their potential harm.

The rearrangement is highly compensated by an adaptation, says co-lead researcher Alexandre Reymond, director of the Center for Integrative Genomics at the Universit de Lausanne in Switzerland.

The extra copies are unique to humans, who typically have six. Our closest ancestors Neanderthals, Denisovans and chimpanzees each have only two, suggesting that the repeats confer an important evolutionary advantage. What that advantage is, however, has been a mystery.

One clue lies in the genes function: BOLA2 helps proteins capture iron. Having fewer repeats is associated with anemia, the researchers found.

Its very interesting, says Emily Casanova, research assistant professor of biomedical sciences at the University of South Carolina in Greenville, who was not involved in the study. My only question is why BOLA2 duplications would have been selected for. What might have been some of the driving factors?

BOLA2 repeats flank a stretch of chromosome 16 called 16p11.2, a hotspot for deletions and duplications that can lead to autism. As eggs and sperm form, the BOLA2 repeats cause DNA to break and rejoin in unusual ways in the 16p11.2 region.

Reymond and his colleagues counted BOLA2 repeats in 130 people who have a deletion of 16p11.2 and in the genetic sequences of 635 controls from two data repositories.

They found that 16p11.2 deletion carriers tend to have fewer BOLA2 repeats than controls do: four as opposed to the usual six. The findings suggest that some BOLA2 copies are lost when deletions in 16p11.2 form.

Because BOLA2 helps proteins latch onto iron, the researchers wondered whether too little of it has consequences for red blood cells; iron is crucial for the cells to transport oxygen.

The researchers analyzed blood samples and medical information from 83 deletion carriers. They found that 8 of the 15 people with only three BOLA2 repeats have signs of anemia, compared with 5 of 68 who have four or more repeats.

The researchers found a similar pattern when they examined genetic and medical information for 379,474 people in the UK Biobank. They found anemia in 20 percent of people with a 16p11.2 deletion, compared with 5 percent of controls. (Anemias prevalence in people with a duplication is no different than in controls.)

Mice missing a copy of 16p11.2 also have low iron levels, and their red blood cells show signs of mild anemia, the team found. Two strains of mice that lack one or both of their copies of BOLA2 show similar traits. The findings were published 7 November in the American Journal of Human Genetics.

The results jibe with those from a March study, in which researchers found an increased risk of anemia in people with a 16p11.2 deletion2.

The link of the BOLA2 copy number to anemia is quite strong, says Bernard Crespi, professor of evolutionary biology at Simon Fraser University in Vancouver, Canada, who was not involved in the study. Why humans evolved a higher number of BOLA2 genes, thats the hard question.

The factors that selected for extra BOLA2 copies remain a mystery. Having extra BOLA2 might have been beneficial as early humans shifted away from a diet based on red meat to one that is less rich in iron, Reymond says. Or perhaps the repeats arose because they protect people from infections, he says: Many pathogens depend on iron they scavenge from their hosts, and BOLA2 might interfere with that process.

Here is the original post:
Gene repeats tied to autism may prevent anemia - Spectrum

Posted in Human Genetics | Comments Off on Gene repeats tied to autism may prevent anemia – Spectrum

Page 1,229«..1020..1,2281,2291,2301,231..1,2401,250..»